Assessment of the role of serum ischemia-modified albumin in obstructive sleep apnea in comparison with interleukin-6. Issue 6 (17th August 2016)

• Record Type: Journal Article
• Authors: Dogan, Deniz; Ocal, Nesrin; Aydogan, Mehmet; Tasci, Canturk; Arslan, Yakup; Tapan, Serkan; Yetkin, Sinan; Bilgic, Hayati
• Is Part Of: Postgraduate medicine. Volume 128:Issue 6(2016)
• Page Start: 603
• Page End: 608
• Publication Date: 2016-08-17
• Subjects: Biomarker -- interleukin-6 -- ischemia-modified albumin -- obesity -- sleep apnea; Medicine -- Periodicals; Medicine -- Periodicals; Medicine; Periodicals; 610.5
• DOI: 10.1080/00325481.2016.1203237
• Languages: English
• ISSNs: 0032-5481

Abstract

ABSTRACT: Objectives : There is limited and contradictory information regarding the role of serum ischemia-modified albumin (IMA) in obstructive sleep apnea (OSA). In this study we examine the effects of OSA and obesity on IMA and interleukin-6 (IL-6), and detect whether IMA and IL-6 may be potential biomarkers in OSA. Methods : Fifty-one males who underwent all night polysomnography test were included into the study. Body-mass index (BMI) and apnea-hypopnea index (AHI) of all patients were determined. Serum IMA and IL-6 levels, erythrocyte sedimentation rate (ESR), complete blood count, routine blood biochemistry and thyroid function tests were performed. Results : Mean IMA [0.36 (± 0.04) U/ml, 0.89 (± 0.15) U/ml], mean IL-6 [1.01 (± 0.19) pg/ml, 2.02 (± 1.19) pg/ml] and mean ESR [4.14 (± 2.5) mm/h, 14.35 (± 13.7) mm/h] levels showed significant difference between non-OSA and OSA groups (P = 0.005, P < 0.001, P < 0.001, respectively). Sensitivity of IMA in distinction of non-OSA/OSA was equal to IL-6 and higher than ESR. IMA was also a stronger predictive factor than IL-6 and ESR in the evaluation of OSA groups (severe/mild/moderate OSA and non-OSA). IMA was the sole distinctive biomarker in assessment of obese and non-obese cases. IMA correlated with IL-6, AHI and ESR. Conclusion : Serum IMA may be a valuable oxidative stress indicator for OSA and could act as a better biomarker than IL-6 for reflecting the presence and the severity of OSA.